AbbVie announces EU progress with RINVOQ, shares trade near 52-week high

By Christina Vogel, Background & Management desk. Reviewed prior to publication on 2026-06-29, 12:15.

AbbVie Inc. (US00287Y1091) highlights fresh momentum from Brussels. The NYSE-listed biopharma group reports that the European Medicines Agency’s CHMP has issued a positive opinion for the JAK inhibitor upadacitinib (RINVOQ) to treat severe alopecia areata in adults and adolescents, according to a company press release and market coverage. Investing.com summary of AbbVie’s CHMP opinion

What the CHMP opinion covers

The CHMP recommendation spans 15 mg and 30 mg once-daily doses of upadacitinib, marketed in Europe under the RINVOQ brand for various inflammatory indications. Canadian Investing.com report on RINVOQ The opinion targets adult and adolescent patients with severe alopecia areata, a disease area where approved treatment options remain limited and cosmetic impact is high. EU-focused coverage of the alopecia indication

Regulators based their stance on data from the Phase 3 UP-AA program, which included two randomized, placebo-controlled, double-blind studies in adult and adolescent patients with severe alopecia areata and assessed both efficacy and safety over time. Details on the UP-AA Phase 3 program The next procedural step is a final decision from the European Commission, expected in the coming months; historically, CHMP positive opinions tend to translate into EU-wide marketing authorizations, though timing can vary by indication.

Pipeline, analyst sentiment and S&P 500 context

The CHMP move adds to a sequence of regulatory and business updates around AbbVie’s immunology franchise. In recent weeks, the company secured FDA approval for Skyrizi to treat children aged six and older with moderate-to-severe plaque psoriasis or active psoriatic arthritis, including a new 55 mg pre-filled syringe for patients under 40 kilograms, complementing the existing 150 mg presentations for heavier patients. Investing.com note on pediatric Skyrizi approval

AbbVie also announced a definitive agreement to acquire Apogee Therapeutics for about $10.9 billion, paying $135.11 per share to secure clinical-stage assets in inflammatory and immunological diseases that fit alongside its established brands in rheumatology and dermatology. Coverage of the Apogee Therapeutics acquisition terms The company, a constituent of the S&P 500 index via its NYSE listing under the ticker ABBV, thus continues to deploy capital into growth areas while maintaining a sizable dividend stream for shareholders. MarketBeat profile for AbbVie shares on the NYSE

The business behind RINVOQ and Skyrizi

AbbVie generates a substantial share of its revenue from immunology medicines, with RINVOQ and Skyrizi positioned as next-generation growth drivers alongside legacy franchises. RINVOQ is already approved in indications such as rheumatoid arthritis, atopic dermatitis and ulcerative colitis, where AbbVie competes directly with peers including Johnson & Johnson, Novartis and Eli Lilly across biologic and small-molecule therapies. MarketBeat overview of AbbVie’s pipeline and growth narrative

Skyrizi contributes in dermatology and gastroenterology, with the expanded pediatric psoriasis and psoriatic arthritis label widening the addressable patient base and underpinning long-term volume growth. Note on Skyrizi’s pediatric approval and dosing The planned Apogee Therapeutics acquisition adds clinical-stage candidates targeted at inflammatory pathways, which could complement or diversify AbbVie’s immunology offerings if late-stage data are positive and regulators grant approvals.

Where the AbbVie shares trade today

AbbVie shares (US00287Y1091) most recently closed at 253.35 US dollars on the NYSE on 2026-06-26, implying a market capitalization around 447.60 billion US dollars and placing the stock close to its 52-week high after a 43 percent gain over the past year. TradingKey data on AbbVie’s latest close and market cap The shares trade as of that date in the large-cap pharmaceutical segment within the S&P 500 and carry an indicated dividend yield slightly above 3 percent based on recent price levels. TrendSpider snapshot of ABBV price, yield and performance

Disclaimer: This article is for informational purposes only and does not constitute investment advice, a recommendation or an offer to buy or sell any securities.